Whitehawk Therapeutics (WHWK) Net Equity Issued and Repurchased (2017 - 2020)

Whitehawk Therapeutics (WHWK) has reported Net Equity Issued and Repurchased for 3 consecutive years, with $9.3 million the latest figure, recorded in Q3 2020.

• In Q3 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $9.3 million; the TTM figure through Dec 2022 stood at $9.3 million (changed 0.0% YoY), while the FY2021 annual figure was $155.0 million, up 1490.78% from the prior year.
• Net Equity Issued and Repurchased rose to $9.3 million in Q3 2020 per WHWK's latest filing, from $6.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $40.2 million in Q1 2017 and bottomed at $2.0 in Q4 2017.
• Historically, Net Equity Issued and Repurchased has averaged $14.0 million across 3 years, with a median of $8.0 million in 2018.